Monlutenca (Lutetium (177lu) Chloride)

Lutetium-177 chloride, the active ingredient in Monlutenca, is a radiopharmaceutical presented as a sterile injectable solution for intravenous use. It delivers targeted beta radiation to specific tumor cells and is employed in the treatment of certain advanced cancers.\n\nGNH India supplies Monlutenca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Monlutenca is a radiopharmaceutical that targets tumour cells expressing specific molecular markers.\n\nNeuroendocrine tumors: provides targeted beta radiation to somatostatin‑receptor positive tumours, helping to control disease progression.\nProstate cancer (PSMA‑positive): delivers radiation to PSMA‑expressing prostate cancer cells in advanced disease.\nMetastatic solid tumours (investigational): under clinical study for use as a targeted radionuclide therapy in selected metastatic cancers.

Monlutenca may be associated with a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea: mild to moderate upset stomach.\n- Fatigue: transient tiredness after infusion.\n- Dry mouth: reduced salivation.\n- Transient hematologic changes: temporary decrease in blood cell counts.\n- Mild abdominal pain: discomfort in the stomach area.\n- Decreased appetite: reduced desire to eat.\n\nSerious or Rare Side Effects:\n- Severe myelosuppression: profound reduction in blood cells requiring medical intervention.\n- Renal toxicity: impaired kidney function.\n- Hepatic toxicity: liver enzyme elevations.\n- Secondary malignancies: rare risk of new cancers due to radiation exposure.\n- Severe allergic reactions: anaphylaxis or hypersensitivity.\n- Pulmonary toxicity: lung inflammation or damage.

Prior to initiating Monlutenca therapy, several safety considerations should be observed.\n\nRenal function: assess baseline kidney function and monitor throughout treatment.\nHematologic status: perform complete blood counts before and after each dose.\nPregnancy: contraindicated in pregnant patients; ensure effective contraception.\nConcurrent chemotherapy: evaluate for additive myelosuppressive effects.\nRadiation safety: follow institutional protocols to protect staff and environment.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze.

Monlutenca may interact with other medicines or therapies that affect blood cells or organ function.\n\nMajor Interactions (Avoid):\n- High‑dose chemotherapy: may cause severe myelosuppression.\n- Nephrotoxic agents: increase risk of renal damage.\n- Radiation sensitizers: amplify radiation effects.\n- Immunosuppressants: heightened infection risk.\n- Other radionuclide therapies: cumulative radiation exposure.\n\nModerate Interactions (Monitor Closely):\n- Antihypertensives: monitor blood pressure due to possible fluid shifts.\n- Diuretics: adjust dosing based on renal function.\n- Antiemetics: may mask nausea symptoms.\n- Blood transfusions: coordinate timing relative to therapy.\n- Hormonal therapies: observe for additive side effects.